Midazolam metabolism by modified Caco-2 monolayers: Effects of extracellular protein binding

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 2, 1999, Pages 1143-1150

  Fisher, Jeannine M ^b   Wrighton, Steven A ^b   Calamia, Justina C ^a   Shen, Danny D ^a   Kunze, Kent L ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN SERUM ALBUMIN; MIDAZOLAM;

ANXIETY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG ISOLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; FIRST PASS EFFECT; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALGORITHMS; CACO-2 CELLS; ELECTRIC CONDUCTIVITY; EXTRACELLULAR MATRIX PROTEINS; EXTRACELLULAR SPACE; HUMANS; HYDROXYLATION; MIDAZOLAM; PROTEIN BINDING; SERUM ALBUMIN;

EID: 0032903501     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Alsenz J, Steffen H and Alex R (1998) Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 15:423-427.
2. Artursson P and Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
3. Boulenc X (1997) Intestinal cell models: Their use in evaluating the metabolism and absorption of xenobiotics. S. T. P. Pharma Sci 7:259-269.
4. de Waziers I, Cugnenc PH, Yang CS, Leroux JP and Beaune PH (1990) Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
5. Dundee JW, Halliday NJ, Harper KW and Brogden RN (1984) Midazolam. A review of its pharmacological properties and therapeutic use. Drugs 28:519-543.
6. 3 modified Caco-2 cell monolayers. J Pharmacol Exp Ther 289:1134-1142.
7. Gan LL, Modeley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW and Thakker DR (1996) CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporine A in Caco-2 cells. Drug Metab Dispos 24:344-349.
8. Ghosal A, Satoh H, Thomas PE, Bush E and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
9. Gillette JR and Pang KS (1977) Theoretical aspects of pharmacokinetic drug interactions. Clin Pharmacol Ther 22:623-639.
10. Gorski JC, Hall SD, Jones DR, Vanden Branden M and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
11. Gres M, Julian B, Bourrié M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y and Fabre G (1998) Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line. Pharm Res 15:726-733.
12. Gwilt PR, Comer S, Chaturvedi PR and Waters DH (1988) The influence of diffusional barriers on presystemic gut elimination. Drug Metab Dispos 16:521-526.
13. Heizmann P and Ziegler WH (1981) Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneim-Forsch 13:2220-2223.
14. Hunter J, Jepson MA, Tsuruo T, Simmons NL and Hirst BH (1993) Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 268:14991-14997.
15. Klippert P, Borm P and Noordhoek J (1982) Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetic data: Correlation with in vivo data using mucosal blood flow. Biochem Pharmacol 31:2545-2548.
16. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
17. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
18. Meunier V, Bourrie' M, Berger Y and Fabre G (1995) The human intestinal epithelial cell line Caco-2: pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11:187-194.
19. Mistry M and Houston B (1987) Glucuronidation in vitro and in vivo. Drug Metab Dispos 15:710-717.
20. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
21. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
22. Pond SM and Tozer TN (1984) First-pass elimination. Clin Pharmacokinet 9:1-25.
23. 3. Mol Pharmacol 51:741-754.
24. Smith MT, Eadie MJ and Brophy TO (1981) The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 19:271-278.
25. Thummel KE, Kunze KL and Shen DD (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Delivery Rev 27:99-127.
26. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
27. Watkins PB, Wrighton SA, Schuetz EG and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
28. Wilkinson GR (1983) Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 14:427-465.